Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Rising Penny Stocks To Buy

This article presents an overview of the 5 Best Rising Penny Stocks To Buy. For a detailed overview of such stocks, read our article, 12 Best Rising Penny Stocks To Buy.

5. Monopar Therapeutics (NASDAQ:MNPR)

Number of Hedge Fund Investors: 2

Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program. The company’s treatment targets cancers expressing the urokinase plasminogen activator receptor, or uPAR, which includes a majority of triple-negative breast, colorectal and pancreatic cancers.

4. Karyopharm Therapeutics Inc (NASDAQ:KPTI)

Number of Hedge Fund Investors: 18

Karyopharm Therapeutics Inc (NASDAQ:KPTI) soared after Novartis acquired oncology-focused company MorphoSys AG for $2.9 billion. Most of the stock gains of Karyopharm Therapeutics Inc (NASDAQ:KPTI) came because of heightened expectations that Karyopharm Therapeutics Inc (NASDAQ:KPTI) could also be a takeover target sometime in the future.

RBC analyst Brian Abrahams, who has a $3 price target on Karyopharm Therapeutics Inc (NASDAQ:KPTI), said the following in a note:

“We see potential readthrough to KPTI — one of few, if not the only, biotech companies whose asset is also in ph.III development for MF (though unlike MOR’s pelabresib has not yet enterested ph. III). At a  <$200 million makret cap, even after today’s move, and with additional opportunity in endoemtrial cancer as well as a possibly a larger cancer company could ultimately be interested in acquiring them for sellinexor as well, we continue to see upside for the shares, and would remain buyers into strength.”

3. Allogene Therapeutics Inc (NASDAQ:ALLO)

Number of Hedge Fund Investors: 20

Clinical-stage immune oncology company Allogene Therapeutics Inc (NASDAQ:ALLO) shares have gained about 40% over the past one month.

In January Allogene Therapeutics Inc (NASDAQ:ALLO) announced a pipeline shakeup that it said would reduce cash burn and would affect about 22% of its workforce.

2. Mersana Therapeutics Inc (NASDAQ:MRSN)

Number of Hedge Fund Investors: 20

Insider Monkey’s database of 933 hedge funds updated as of the end of 2023 shows that 20 funds had stakes in  Mersana Therapeutics Inc (NASDAQ:MRSN). The stock has gained about 22% over the past one month.

Last month, Mersana Therapeutics Inc (NASDAQ:MRSN) reported enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC. Mersana Therapeutics Inc (NASDAQ:MRSN) expects to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024.

1. Taysha Gene Therapies Inc (NASDAQ:TSHA)

Number of Hedge Fund Investors: 20

Taysha Gene Therapies Inc (NASDAQ:TSHA) have skyrocketed by 63% over the past one month.

A total of 20 hedge funds out of the 933 funds in Insider Monkey’s database had stakes in Taysha Gene Therapies Inc (NASDAQ:TSHA). The biggest stake in Taysha Gene Therapies Inc (NASDAQ:TSHA) is owned by  Peter Kolchinsky’s RA Capital Management which owns a $33 million stake in Taysha Gene Therapies Inc (NASDAQ:TSHA).

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also look at the 13 Best NASDAQ Penny Stocks To Invest In and the 15 Cash-Rich Penny Stocks Hedge Funds Are Buying.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.